| scholarly article | Q13442814 |
| P50 | author | Maria Luisa Brandi | Q29839820 |
| Loredana Cavalli | Q55207642 | ||
| P2860 | cites work | Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women | Q24242258 |
| Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women | Q24242674 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis | Q28241336 | ||
| Increasing options for the treatment of osteoporosis | Q28254516 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin | Q28295204 | ||
| Denosumab in postmenopausal women with low bone mineral density | Q28298728 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. | Q33913012 | ||
| Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. | Q33985248 | ||
| Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis | Q34003925 | ||
| Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial | Q34011999 | ||
| Bisphosphonates: the first 40 years | Q34026820 | ||
| The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). | Q45105108 | ||
| Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats | Q45146640 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. | Q45931469 | ||
| Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells | Q46042275 | ||
| Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis | Q46065460 | ||
| Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial | Q46110515 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). | Q46219189 | ||
| How drugs decrease fracture risk: lessons from trials. | Q46368142 | ||
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 | ||
| Trabecular bone microarchitecture after alendronate treatment of osteoporotic women | Q46414279 | ||
| Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial | Q46551911 | ||
| Strontium ranelate does not stimulate bone formation in ovariectomized rats. | Q46666653 | ||
| Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study | Q46855739 | ||
| A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 | ||
| Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. | Q51020357 | ||
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 | ||
| Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD | Q58971166 | ||
| Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 | ||
| Bisphosphonate mechanism of action | Q73011879 | ||
| Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase | Q73212125 | ||
| Alendronate induces gastric injury and delays ulcer healing in rodents | Q74098992 | ||
| Treatment of postmenopausal osteoporosis | Q74332861 | ||
| Comparative study of potential for bisphosphonates to damage gastric mucosa of rats | Q74558098 | ||
| Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures | Q77134968 | ||
| Induction of a program gene expression during osteoblast differentiation with strontium ranelate | Q79774924 | ||
| Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84 | Q79787314 | ||
| To stop or not to stop, that is the question | Q83033686 | ||
| Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women | Q83371794 | ||
| Denosumab-related osteonecrosis of the jaws | Q83816152 | ||
| Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients | Q84062765 | ||
| "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws | Q84402689 | ||
| Osteonecrosis of the jaw in patients receiving oral bisphosphonates | Q84796130 | ||
| Minireview: the OPG/RANKL/RANK system | Q34102256 | ||
| Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling | Q34384039 | ||
| Appropriate use of anabolic treatment for severe osteoporosis | Q34417198 | ||
| Mechanisms of action and therapeutic potential of strontium in bone | Q34421242 | ||
| Treatment and prevention of bone complications from prostate cancer | Q34441944 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women | Q34656025 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| Efficacy and safety of bazedoxifene for postmenopausal osteoporosis | Q35092811 | ||
| Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 | ||
| Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis | Q35867231 | ||
| Mechanism of action of bisphosphonates | Q36203193 | ||
| Determinants of skeletal fragility | Q36318781 | ||
| Osteoclast precursors, RANKL/RANK, and immunology | Q36324916 | ||
| The role of the immune system in the pathophysiology of osteoporosis | Q36324969 | ||
| Factors associated with osteonecrosis of the jaw among bisphosphonate users | Q37012912 | ||
| Effects of teriparatide retreatment in osteoporotic men and women | Q37257574 | ||
| Osteoporosis: an age-related and gender-specific disease--a mini-review | Q37307341 | ||
| Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. | Q37336471 | ||
| Osteoblasts play key roles in the mechanisms of action of strontium ranelate | Q37346557 | ||
| Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. | Q37523548 | ||
| Microarchitecture, the key to bone quality | Q37604092 | ||
| Treatment of osteoporosis with denosumab | Q37710822 | ||
| Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis | Q37731528 | ||
| Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review | Q37792889 | ||
| Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis | Q39124107 | ||
| The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation | Q40127318 | ||
| Bone mineral density thresholds for pharmacological intervention to prevent fractures | Q40508494 | ||
| Nonclinical model for assessing gastric effects of bisphosphonates | Q40905871 | ||
| Esophagitis associated with the use of alendronate | Q41102881 | ||
| The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | Q41649459 | ||
| Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo | Q41753607 | ||
| Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms | Q42526271 | ||
| Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years | Q42630575 | ||
| Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. | Q43168771 | ||
| Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis | Q43812611 | ||
| Alendronate disturbs vesicular trafficking in osteoclasts | Q43926696 | ||
| Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography | Q44578541 | ||
| Ten years' experience with alendronate for osteoporosis in postmenopausal women | Q44804093 | ||
| Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. | Q44961457 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 253-266 | |
| P577 | publication date | 2012-06-11 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility | |
| P478 | volume | 8 |
| Q35087883 | Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain |
| Q36309349 | Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years |
| Q27024847 | Periprosthetic bone loss: diagnostic and therapeutic approaches |
| Q27024555 | The clinical approach toward giant cell tumor of bone |
| Q36202821 | Treatment options for postmenopausal osteoporosis |
Search more.